IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

RUSCONI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 20.302
NA - Nord America 19.627
AS - Asia 15.320
SA - Sud America 1.984
AF - Africa 815
OC - Oceania 132
Continente sconosciuto - Info sul continente non disponibili 25
Totale 58.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.804
GB - Regno Unito 6.166
CN - Cina 5.121
SG - Singapore 4.846
IT - Italia 4.329
DE - Germania 2.607
BR - Brasile 1.504
SE - Svezia 1.443
HK - Hong Kong 1.410
RU - Federazione Russa 1.281
IN - India 917
NL - Olanda 723
IE - Irlanda 715
FR - Francia 704
CA - Canada 623
FI - Finlandia 619
TR - Turchia 549
KR - Corea 544
VN - Vietnam 449
ID - Indonesia 410
UA - Ucraina 393
ES - Italia 317
JP - Giappone 299
CI - Costa d'Avorio 165
EU - Europa 164
BE - Belgio 160
MX - Messico 146
ZA - Sudafrica 146
AR - Argentina 144
PL - Polonia 143
DK - Danimarca 136
CO - Colombia 134
AU - Australia 120
AT - Austria 103
CH - Svizzera 100
TW - Taiwan 91
TH - Thailandia 88
GR - Grecia 87
PH - Filippine 81
BD - Bangladesh 69
IQ - Iraq 64
RO - Romania 56
PT - Portogallo 54
UG - Uganda 53
EC - Ecuador 52
GH - Ghana 50
ET - Etiopia 49
PK - Pakistan 49
NG - Nigeria 48
IR - Iran 47
CL - Cile 45
KE - Kenya 43
SA - Arabia Saudita 40
MA - Marocco 39
IL - Israele 35
NO - Norvegia 35
UZ - Uzbekistan 31
PE - Perù 30
VE - Venezuela 30
MY - Malesia 29
EG - Egitto 28
CM - Camerun 22
AE - Emirati Arabi Uniti 21
JO - Giordania 20
PY - Paraguay 19
CZ - Repubblica Ceca 18
TN - Tunisia 18
TZ - Tanzania 18
ZM - Zambia 17
TG - Togo 15
BG - Bulgaria 13
DZ - Algeria 13
UY - Uruguay 13
LT - Lituania 12
NP - Nepal 12
HU - Ungheria 11
NZ - Nuova Zelanda 11
OM - Oman 11
AL - Albania 10
JM - Giamaica 10
KZ - Kazakistan 10
PA - Panama 10
RS - Serbia 10
AM - Armenia 9
MK - Macedonia 9
MZ - Mozambico 9
A2 - ???statistics.table.value.countryCode.A2??? 8
AZ - Azerbaigian 8
BW - Botswana 8
DO - Repubblica Dominicana 8
LB - Libano 8
BO - Bolivia 7
CR - Costa Rica 7
KG - Kirghizistan 7
LU - Lussemburgo 7
SC - Seychelles 7
SL - Sierra Leone 7
CU - Cuba 6
EE - Estonia 6
LK - Sri Lanka 6
Totale 58.198
Salva come PNG Salva come JPEG
Città #
Southend 5.365
Singapore 2.501
Ashburn 1.896
Chandler 1.397
Fairfield 1.287
Hong Kong 1.211
Milan 1.198
Frankfurt am Main 1.050
Seattle 984
Beijing 893
Dallas 822
Houston 813
Wilmington 775
Dublin 706
Woodbridge 646
Princeton 645
Ann Arbor 580
Council Bluffs 520
Cambridge 434
Los Angeles 428
Hefei 389
San Jose 385
Boardman 374
Helsinki 345
Santa Clara 344
Bengaluru 327
Jakarta 320
Toronto 315
Redwood City 300
Dearborn 288
Nanjing 260
Des Moines 247
Buffalo 234
Redmond 222
Guangzhou 217
Jacksonville 217
Rome 216
Shanghai 207
Hanover 188
Moscow 176
The Dalles 173
Mountain View 172
New York 166
Abidjan 160
Phoenix 158
Seoul 147
Tokyo 140
São Paulo 138
Columbus 133
Munich 129
Sakarya 128
Ho Chi Minh City 127
Ottawa 123
Istanbul 121
Cangzhou 118
Brussels 109
Nuremberg 108
Jinan 106
Chicago 105
Shenyang 105
London 104
Warsaw 100
Somerville 95
Mumbai 89
Tianjin 88
Serra 85
Bogotá 79
Hanoi 79
Boise 75
Silver Spring 75
Andover 74
Central District 72
San Diego 72
Berlin 71
Hebei 67
Taipei 66
Changsha 65
Nanchang 63
Hangzhou 62
Athens 60
Turin 60
Bodio Lomnago 59
Dong Ket 59
Margão 58
Grafing 56
Valencia 56
Fuzhou 55
Zhengzhou 54
Kent 50
Rio de Janeiro 50
Montreal 49
Shenzhen 48
Vienna 48
Boston 47
Paris 47
Belo Horizonte 46
Fremont 46
Jiaxing 46
Atlanta 45
Daejeon 45
Totale 34.953
Salva come PNG Salva come JPEG
Nome #
Mapping the human genetic architecture of COVID-19 822
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients 788
Renal complications in HIV disease : between present and future 775
Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets 602
Self-reported symptoms of SARS-CoV-2 infection in a non-hospitalized population : results from the large Italian web-based EPICOVID19 cross-sectional survey. (Preprint) 521
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 520
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 488
Five years with dolutegravir plus lamivudine as a switch strategy : much more than a positive finding 399
Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes 387
Efficacy and tolerability of multiple drug therapy in HIV-infected children 376
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 362
The problem of renal function monitoring in patients treated with the novel antiretroviral drugs 351
Description of a "Trans-Saharan" strain of human T-Lymphotropic virus type 1 in West Africa 345
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial 330
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 309
Failure to eradicate HIV despite fully successful HAART initiated in the first days of life 300
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir 295
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens 295
Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau 291
Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort 291
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA) 290
A novel methodology for large-scale phylogeny partition 290
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 289
Safety of statin therapy in HIV/hepatitis C virus-coinfected patients 288
Prevalence of HIV-1 resistant strains in recent seroconverters 287
Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort 286
Gammaglutamyltranspeptidase (gamma-GT) levels before treatment are predictive of Tipranavir interruption in ART multiexperienced HIV-1-infected patients 285
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region : outcome after treatment in recently infected individuals 283
Is the rate of virological failure to cART continuing to decline in recent calendar years? 282
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation 280
Italian consensus statement on management of HIV-infected individuals with advanced disease naive to antiretroviral therapy 277
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting 276
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART 274
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 274
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study 270
In vitro efficacy of a non-conventional (folding) HIV-1 protease inhibitor without selection of resistance 268
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 267
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 264
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts : Data from the Icona Foundation Cohort 262
Vpr and HIV-1 disease progression : R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients 260
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype 260
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients : results from a multicenter cohort study 260
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST 258
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status 256
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 255
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 254
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects 254
Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results 253
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 253
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection 252
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression : 48-week efficacy and safety results 252
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 251
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV : experience in a pediatric population 250
Genomic characterisation and phylogenetic analysis of SARS-COV-2 in Italy 248
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 247
Enhancing care for people living with HIV: current and future monitoring approaches 246
The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated : results from a prospective study 245
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates 240
Clinical pharmacology in HIV cure research : what impact have we seen? 240
Durability of INI-containing regimens after switching from PI-containing regimens : a single-centre cohort of drug-experienced HIV-infected subjects 240
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A. : a modelling study 236
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses 233
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro 231
Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection : in vitro studies of mixed virus infections 230
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 229
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 224
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 223
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART 223
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study 223
PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response 223
Unusual codon 69 insertions : influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility 222
Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus 221
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART 220
Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study 220
Clinical and genetic determinants of nevirapine plasma trough concentration 219
Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol 217
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I 217
Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation 216
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 214
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2] 211
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection 211
Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study 211
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients 210
The non-conventional (folding) protease inhibitor blocks the human immunodeficiency virus type-1 replication without evidence of resistance during in vitro passage 208
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy : 48-Week results of a randomized trial 207
Epidemiological spread of drug-resistant HIV-1 strains 206
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen : a retrospective cohort study 205
Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine 204
Human-to-Cat SARS-CoV-2 Transmission: Case Report and Full-Genome Sequencing from an Infected Pet and Its Owner in Northern Italy 204
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study 203
Disappearance of cryoglobulins and remission of symptoms in a patient with HCV-associated type II mixed cryoglobulinemia after HIV-1 infection 202
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy : A postauthorization noninterventional study 202
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 201
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection 201
Differences in the prevalence of SARS-COV-2 infection and access to care between italians and non-italians in a social-housing neighbourhood of Milan, Italy 201
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting : data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 200
AIDS in a long-term HIV-1-infected patient with a stable high CD4+ cell count and conserved CD4+CD45RO+ subpopulation 199
Self-reported Olfactory and Taste Disorders in Patients with Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study 199
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 198
Discontinuation of initial antiretroviral therapy in clinical practice : Moving toward individualized therapy 197
Totale 27.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.955
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.955
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.992 0 0 0 0 0 0 374 465 550 444 787 372
2021/20224.905 381 336 267 267 339 280 357 490 593 474 294 827
2022/20235.977 661 555 492 663 589 1.038 216 370 699 142 332 220
2023/20245.055 241 364 257 333 869 492 390 329 211 361 535 673
2024/202510.050 467 1.012 332 956 706 581 545 1.022 614 917 959 1.939
2025/202611.827 1.908 1.534 2.193 1.757 2.007 1.655 773 0 0 0 0 0
Totale 60.520